BenevolentAI Investor Presentation Deck
Poised for growth and success
Strengthened financial position enhances our leadership position in Al-enabled drug
discovery and enable us to:
✓ Independently pursue the clinical development of certain in-house pipeline assets in core
therapeutic areas
✓ Out-license multiple assets over the next 1-3 years to strengthen our balance sheet and
drive long term value creation
✓ Increase the size of our pipeline with a healthy balance of new first-in-class and
best-in-class assets with 1-2 CTA/IND-stage drug candidates every year
✔ Sign new collaboration agreements with pharma companies to to leverage our disease
agnostic capabilities into therapeutic indications outside our focus areas, to generate
incremental revenue
✔ Maintain our leading position in Target ID through increased investment in our technology
capabilities
✓ Build out our technology metrics to exemplify the differentiation of our approach
Benevolent 24View entire presentation